세계 올리고뉴클레오티드 합성 시장 규모는 2023년 60억 6,000만 달러에서 2031년 187억 6,000만 달러로 2024-2031년 예측 기간 동안 15.17%의 CAGR로 성장할 것으로 예상됩니다. 시장 성장은 제약 및 생명공학 부문의 R&D 투자 증가, 다양한 기업 간의 공동 연구 및 파트너십 증가, 만성 질환의 유행, 법의학 및 유전자 검사, 연구 활동에 사용되는 맞춤형 올리고뉴클레오티드에 대한 수요 증가에 의해 뒷받침되고 있습니다.
연구 개발 투자 증가는 올리고뉴클레오티드 합성 시장의 세계 주요 트렌드이며, 2023년 9월 스페인의 주요 제약 회사 중 하나인 Insud Pharma Group은 Chemo India Formulation Private Limited에 올리고뉴클레오티드 센터를 설립했습니다. 이 연구 및 생산 센터는 올리고뉴클레오티드의 상업적 생산 및 연구에 초점을 맞추고 있습니다. 이 시설은 인도 약물통제센터(Drug Control Center of India), 스페인 보건청(Spanish Health Agency), 미국 FDA(미국 식품의약국)의 검사 및 승인을 받았습니다.
새로운 제품과 기술의 도입은 시장에 유리한 성장 기회를 제공합니다. 2024년 4월, Asahi Kasei Bioprocess Inc.는 최신 오리오 제조 혁신인 THESYS ACS ERGO 합성 컬럼을 발표했습니다. 이 컬럼은 제품 품질을 유지하고 사용자의 안전을 유지하면서 전환 시간을 단축하는 동시에 작업자 친화적인 설계로 안전하고 원활한 전환이 가능하도록 설계되어 배치 간 비효율을 줄일 수 있도록 설계되었습니다. THESYS ACS ERGO의 시간 절약 기능은 유지보수 및 교체 과정에서 나사 볼트를 사용하지 않음으로써 달성됩니다.
M&A가 시장 확장을 지원
시장 성장을 뒷받침하는 것은 전 세계 여러 지역에서 M&A와 제휴가 증가하고 있다는 점입니다. 이러한 활동을 통해 기업들은 성공적인 공동연구를 통해 첨단 기술의 발견, 제공 및 개발을 보장할 수 있으며, M&A는 기업의 유기적 확장을 돕고 R&D 활동과 새로운 치료법 및 기술 개발을 촉진하는 데 필요한 자금을 제공하여 올리고뉴클레오티드 합성 세계 시장 성장을 촉진합니다.
2024년 6월, GSK plc는 올리고뉴클레오티드 치료제의 잠재력을 활용하기 위해 Elsie Biotechnologies, LLC를 5,000만 달러에 인수한다고 발표했습니다. Elsie는 올리고뉴클레오티드는 유전자 발현을 조절하는 독특한 능력을 가지고 있어 저분자 생물학적 제제나 분자로는 대응할 수 없는 광범위한 치료 표적에 대응할 수 있는 잠재력을 가지고 있으며, Elsie는 올리고뉴클레오티드 치료제의 전달 최적화, 독성 감소, 효능 강화에 초점을 맞추고 있습니다. GSK는 Elsie 인수를 통해 유전자 조절 분야의 연구개발을 강화할 수 있을 것으로 기대하고 있습니다. 또한, GSK의 기기 학습 및 AI 활용은 Elsie 플랫폼의 데이터와 결합하여 향후 올리고뉴클레오티드 설계를 간소화하기 위한 예측 모델 개발에 도움이 될 것으로 예상됩니다.
진단 분야에서의 응용 분야 증가로 시장 성장 촉진
다양한 질병과 장애의 유행으로 인한 올리고뉴클레오티드 수요 증가는 올리고뉴클레오티드 합성에 대한 세계 수요를 강화하고 있습니다. 연구 및 진단 응용 분야에서 올리고뉴클레오티드는 다공성 유리(CPG)를 사용하여 합성됩니다. 분자생물학에서 올리고뉴클레오티드는 하이브리드화 분석 및 중합효소 연쇄 반응을 통해 원하는 RNA 및 DNA 서열을 검출하는 데 도움이 됩니다. 올리고뉴클레오티드 기반 마이크로어레이는 다양한 세포 유형 및 조직에서 유전자 발현 수준을 분석하기 위해 개발되었으며, 올리고뉴클레오티드 프로브는 유전자 질환과 관련된 다형성 및 특정 돌연변이를 식별하는 데 사용할 수 있습니다. Epilepsy Foundation의 추산에 따르면, 2만-4만 명 중 1명이 드라베 증후군을 앓고 있으며, 유전성 질환 환자 수가 증가함에 따라 진단 개입을 위한 올리고뉴클레오티드에 대한 수요가 증가하고 있습니다.
이 보고서는 세계 올리고뉴클레오티드 합성 시장에 대해 조사 분석했으며, 시장 규모와 예측, 시장 역학, 주요 기업 현황과 전망 등을 전해드립니다.
Global oligonucleotide synthesis market is projected to witness a CAGR of 15.17% during the forecast period 2024-2031F, growing from USD 6.06 billion in 2023 to USD 18.76 billion in 2031F. The market's growth is supported by the increasing investments towards research and development activities in the pharmaceutical and biotechnology sectors, rising collaborations and partnerships among various companies, growing prevalence of chronic diseases, and rising demand for custom oligonucleotides for use in forensics, genetic testing, and research activities.
Rising research and development investments are a major global trend in the oligonucleotide synthesis market. In September 2023, Insud Pharma Group, one of the leading Spanish pharmaceutical companies, inaugurated its oligonucleotide center at Chemo India Formulation Private Limited. The research and production center will focus on commercial production and research on oligonucleotides. The facility was inspected and approved by the Drug Control Center of India, Spanish Health Agency, and the US FDA (United States Food and Drug Association).
Introducing novel products and technologies provides lucrative growth opportunities to the market. In April 2024, Asahi Kasei Bioprocess Inc. unveiled their latest olio manufacturing innovation, the THESYS ACS ERGO synthesis column, which offers reduced changeover time while maintaining the quality of the product and maintaining user safety. The THESYS ACS ERGO facilitates a safe and smooth changeover between runs with the help of its operator-friendly design and is engineered to reduce inefficiencies between batches. The time-saving feature of the THESYS ACS ERGO is achieved by eliminating the utilization of threaded bolts in the maintenance and changeover process.
Mergers and Acquisitions are Supporting Market Expansion
The growth of the market is supported by the rising mergers and acquisitions and successful collaborations in various regions across the globe. These activities allow companies to follow through with successful research collaborations and ensure the discovery, delivery, and development of advanced technologies. Mergers and acquisitions aid in the company's organic expansion and provide necessary funds for driving research and development activities and development of novel therapies and technologies, thus bolstering the global oligonucleotide synthesis market growth.
In June 2024, GSK plc announced the acquisition of Elsie Biotechnologies, LLC for USD 50 million to capitalize on the potential of oligonucleotide therapeutics. The unique ability of the oligonucleotides to modulate gene expressions makes them a potential modality for addressing a wide range of therapeutic targets that might not be amenable to small biologics and molecules. Elsie is focused on optimizing delivery, reducing toxicity, and enhancing the potency of oligonucleotide therapeutics. With the acquisition of Elsie, GSK is expected to enhance its research and development efforts in gene modulation. Furthermore, the utilization of machine learning and artificial intelligence by GSK, in combination with the data from Elsie's platform, is expected to support the development of predictive models for streamlining future oligonucleotide designs.
Rising Applications in Diagnostics Bolsters the Market Growth
The rising demand for oligonucleotides due to the growing prevalence of various diseases and disorders is bolstering the global demand for oligonucleotide synthesis. For research and diagnostic applications, oligonucleotides are synthesized using controlled pore glass (CPG). In molecular biology, oligonucleotides aid in detecting the desired RNA and DNA sequences using hybridization assays and polymerase chain reactions. The oligonucleotide-based microarrays have been developed to analyze the gene expression levels in various cell types and tissues, and oligonucleotide probes can be used to identify polymorphisms and specific mutations associated with genetic disorders. The rise in the number of cases of genetic disorders is thus bolstering the demand for oligonucleotides for diagnostic interventions. According to the estimates of the epilepsy foundation, 1 in 20,000 to 1 in 40,000 individuals have Dravet Syndrome.
Therapeutics Segment to Account for Significant Global Oligonucleotide Synthesis Market Share
The growth of the segment is aided by the rising prevalence of chronic diseases and increasing utilization of oligonucleotides in drug development processes. Over the past few years' oligonucleotides have demonstrated the ability to provide patients with major therapeutic benefits, future developments are expected to boost the expansion of the segment. The segment's growth is supported by the rise in the number of collaborations to support the discovery and development of oligonucleotide therapeutics. In May 2024, Orbit Discovery Ltd. and Secarna Pharmaceuticals GmbH & Co. entered in a collaboration for developing peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics. The collaboration aims to expand Secarna's reach of antisense approaches and strengthen their ability of creating targeted antisense therapeutics, allowing them to offer novel treatment solutions for a wide range of diseases.
Additionally, the growth of the market is supported by the rising investments in companies that are focused on the development of targeted oligonucleotide therapeutics. In January 2022, Ceptur Therapeutics, Inc. announced the completion of a USD 75 million Series A financing. The biotechnology company focuses on the development of targeted oligonucleotide therapeutics that are based on U1 Adaptor Technology. Such investments are expected to support the development of novel products, propelling the expansion of the segment.
North America Accounts for Significant Market Share
The factors supporting the market's growth in North America include rising investments towards the development of advanced therapeutic solutions, rapid expansion of the healthcare and pharmaceutical sectors, and increasing prevalence of various chronic diseases. According to the estimates of the National Cancer Institute, approximately 2,001,140 cases of cancer and 611,720 deaths from the disease are expected to occur in the United States in 2024.
The growing emphasis on novel product development coupled with rising approvals from the US FDA further supports the market expansion. In June 2024, the FDA approved Geron Corporation's RYTELO (imetelstat), an oligonucleotide telomerase inhibitor for treating adults with low-to-intermediate-1 risk myelodysplastic syndromes (LR-MDS) that have transfusion-dependent anemia and require four or more units of red blood cells over eight weeks. Approval was given based on the safety and efficacy findings from the placebo-controlled, randomized, phase 3 IMerge trial.
Furthermore, rising investments in the development of oligonucleotide manufacturing facilities are supporting the expansion of the market in North America. In November 2023, Integrated DNA Technologies, Inc. opened its new therapeutic oligonucleotide manufacturing facility in Iowa, the United States. The site manufactures gene therapy reagents and cGMP cells, including donor oligos for homology-directed repair and sgRNAs (single guide RNAs).
Future Market Scenario (2024 - 2031F)
The potential applications for oligonucleotide synthesis are expected to expand over the forecast period, from gene regulation to gene editing and personalized medicine, novel applications of oligonucleotide synthesis are anticipated to emerge. Future applications and innovations are expected to increasingly focus on personalized medicines and the designing of oligonucleotides that are capable of targeting specific genomic regions or mutations, strengthening the possibility of developing therapies tailored to specific patient requirements, thus facilitating the growth of the market in the forecast period.
Furthermore, the rise in the number of research activities that use oligonucleotides as interventions or treatments is expected to support the expansion of the market in the coming years. The University College London (UCL) is conducting an interventional study, which is expected to conclude in August 2025, to assess if the drug NIO752 reduces the production of tau protein by the brain. In normal conditions tau is responsible for stabilizing neuronal microtubules, however in Alzheimer's the protein builds up in the brain and causes damage.
Key Players Landscape and Outlook
The rising investments by companies across the globe towards developing oligonucleotide manufacturing facilities is expected to boost the global oligonucleotide synthesis market size. Companies are increasingly focusing on forming strategic partnerships and alliances to support such development activities. In April 2024, Axolabs Gmbh and Asahi Kasei Bioprocess Inc. (AKB), part of the Asahi Kasei Group, announced a partnership to build a cGMP manufacturing facility in Berlin to accelerate the commercialization and development of oligonucleotide-based therapies.
Such investments are increasing as oligonucleotide therapies offer targeted approaches for protein production and gene expression modulation and can potentially treat a broad range of diseases. At present, the FDA has approved eighteen oligonucleotide drugs.
Additionally, the market's growth is supported by the rising investments by the key market players in oligonucleotide manufacturing suites. In March 2024, Merck announced the opening of its first cGMP Oligonucleotide Manufacturing suite in Missouri, the United States. The development is expected to enhance the company's oligo offerings to include cGMP quality oligos tailored for clinical and diagnostic markets.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work